Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05090657 · ClinicalTrials.gov registry record · Phase 2
Nasal Photodisinfection in All Patients Presenting for Surgery for a Wide Range of Surgical Procedures
A Phase 2 study, sponsored by Ondine Biomedical.
- Completed
- Registry status
- Phase 2
- Development phase
- 322
- Enrollment target
NCT05090657: Completed Phase 2 study, sponsored by Ondine Biomedical.
NCT05090657 is a Phase 2 study that has completed, run by Ondine Biomedical. The registered enrollment target is 322 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (142% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05090657, a Phase 2 study, has completed, sponsored by Ondine Biomedical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 322 participants
- Enrollment target
Study Summary
This is a Phase 2 single-center, open-label, single-arm, study of a microbiological endpoint using antimicrobial photodynamic therapy (aPDT) for nasal disinfection in all patients (universal) presenting for surgery at an acute care hospital for a wide range of surgical procedures.
Primary Outcome
All pre-surgical subjects will be screened by plate culture for Staphylococcus aureus nasal carriage. All subjects will receive the nasal decolonization treatment and then be screened again for Staphylococcus aureus carriage.
Interventions
- COMBINATION_PRODUCT methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2022-02-04 |
| Est. Completion | 2022-08-06 |
| Phase | Phase 2 |
What the finished NCT05090657 record still lists
NCT05090657 is an interventional study that assigns participants to a tested intervention. The registered 322 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (142% higher).
The record links to 0 conditions, and to 1 intervention - of which methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation is the first listed.
NCT05090657 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05090657 about?
NCT05090657 is a clinical study titled "Nasal Photodisinfection in All Patients Presenting for Surgery for a Wide Range of Surgical Procedures". This is a Phase 2 single-center, open-label, single-arm, study of a microbiological endpoint using antimicrobial photodynamic therapy (aPDT) for nasal disinfection in all patients (universal) presenting for surgery at an acute care hospital for a wide range of surgical procedures.
What is the current status of trial NCT05090657?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 322 participants. The study started on 2022-02-04. Estimated completion is 2022-08-06.
What interventions are being tested in trial NCT05090657?
The interventions under investigation include: methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05090657?
This trial is sponsored by Ondine Biomedical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05090657's enrollment target sits among peer trials
322 150th of 2000 higher than 1,850 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04090359 · 322 participants · Phase 4
Dual Mobility Acetabular Cups in Revision TJA
- NCT04924075 · 322 participants · Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- NCT03715933 · 321 participants · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- NCT05922878 · 321 participants · Phase 2
Study of ALTO-300 in MDD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI